Immune Cell Staining Panels for Early NPC Risk Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Early diagnosis of nasopharyngeal carcinoma (NPC) is challenging due to variable symptoms and limitations in existing diagnostic tools, leading to frequent diagnosis at advanced stages with poor prognosis, and there is a need for more accurate indicators beyond EBV infection status.
Innovation Solution
A staining kit and method using fluorescently labeled antibodies to identify characterized immune cell subsets, combined with machine learning algorithms, for predicting NPC likelihood by analyzing peripheral blood mononuclear cells (PBMCs) to distinguish immune profiles between patients and healthy controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If nasopharynx imaging and biopsy are used for NPC diagnosis, then diagnostic accuracy is improved, but diagnostic cost and time are increased
Solution Approach 1:
The patent applies preliminary action by using immune cell profiling as a pre-screening tool before definitive imaging and biopsy procedures. The method identifies characteristic immune cell subsets (such as increased regulatory T cells, decreased CD4+ T cells) that correlate with NPC, allowing early-risk identification and triage of patients who most need invasive diagnostic procedures, thereby reducing overall diagnostic time and cost while maintaining accuracy.
Solution Approach 2:
The patent uses immune cell profiles as an intermediary biomarker between non-invasive blood sampling and definitive tissue diagnosis. Instead of directly proceeding to imaging and biopsy, the immune cell analysis serves as a middle step that provides diagnostic information with higher throughput and lower cost, facilitating more efficient patient management.
2Reliability
If anti-EBV antibody or EBV cDNA testing is used, then NPC risk identification is improved, but diagnostic accuracy is reduced due to low specificity
Solution Approach 1:
The patent applies local quality by shifting from a general EBV infection marker (which lacks specificity) to a specific local immune response profile within the blood. Instead of measuring overall EBV presence, the method analyzes the specific distribution and proportions of different immune cell subsets (regulatory T cells, CD4+ T cells, CD8+ T cells, B cells, NK cells) that locally reflect the anti-NPC immune response, thereby achieving high diagnostic accuracy.
Solution Approach 2:
The patent inverts the diagnostic approach by not directly detecting the virus (EBV) but rather detecting the host's immune response to the virus. Instead of asking 'is the virus present?' (which gives false positives), the method asks 'is the immune system mounting a specific response to the virus?' which provides much higher specificity for NPC diagnosis.
3Measurement precision
If comprehensive immune profiling is performed, then diagnostic accuracy is improved, but test complexity is increased
Solution Approach 1:
The patent applies segmentation by dividing the complex immune profiling into distinct, measurable components using flow cytometry panels. Each panel targets specific cell populations (T cells, B cells, NK cells, monocytes) and their functional subsets, allowing systematic analysis of the immune landscape. This segmented approach makes the complex test manageable, reproducible, and suitable for clinical implementation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high accuracy in identifying immune cell subsets and predicting NPC with AUC up to 0.98, sensitivity up to 100%, and specificity up to 90%, providing a novel diagnostic platform for NPC.
Implementation Method 1
A staining kit and method using fluorescently labeled antibodies to identify characterized immune cell subsets
Implementation Method 2
fluorescently labeled antibodies to identify characterized immune cell subsets
Data Source
AI summary
A staining kit is provided, including a first pattern including antibodies against T cell, B cell, NK cell, monocyte, regulatory cell, CD8, CD45, and CTLA4; a second pattern including antibodies against T cell, B cell, NK cell, monocyte, regulatory cell, dendritic cell, and CD45; a third pattern including antibodies against T cell, B cell, NK cell, monocyte, CD8, CD45, CD45RA, CD62L, CD197, CX3CR1 and TCRαβ; and a fourth pattern including antibodies against B cell, CD23, CD38, CD40, CD45 and IgM, wherein the antibodies of each pattern are labeled with fluorescent dyes. A method of identifying characterized immune cell subsets of a disease and a method of predicting the likelihood of NPC in a subject in the need thereof using the staining kit are also provided.